Gritstone Oncology’s goal is to eradicate cancer by developing personalized immunotherapies to fight multiple cancer types. Our approach focuses on the individual nature of a patient’s tumor and seeks to generate a therapeutic immune response in these patients by unleashing the natural power of a patient’s immune system to recognize tumor antigens in order to destroy cancer cells. These antigens, called tumor-specific neoantigens, offer attractive therapeutic targets because they are non-self and tumor-specific, and are key targets for a potent immune response. We believe that activating and directing the immune system to these tumor targets could offer an important opportunity to extend the benefits of immunotherapy for patients with cancer.Read More learn more about antigens
What is a Tumor Antigen?
A small protein on the surface of a tumor cell that functions as the target for T cell mediated tumor death.
Antigens restricted to a certain normal cell type or lineage
Shared Tumor-Associated Antigens
Antigens present in normal cells and overexpressed in cancer cells
Shared Tumor-Specific Antigens
Antigens found in testis and tumor tissue that are functionally tumor specific
Antigens derived from mutated proteins in tumor cells